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Abstract
Background and aims: About one-third of inflammatory bowel disease (IBD) patients still require
surgery. A growing number of them receive anti-tumor necrosis factor (TNF) therapy before
surgery. The present meta-analysis studied the risk of postoperative complications in IBD patients
treated with anti-TNF.
Methods: MEDLINE was searched (up to January 2012) to identify observational studies reporting
the prevalence of postoperative complications in IBD patients. The prevalence of overall, infectious,
and non-infectious postoperative complications was extracted for all studies, and according to
preoperative anti-TNF treatment where reported. Pooled prevalence, as well as odds ratios (ORs),
with 95% confidence intervals (CIs) was calculated.
Results: The search identified 86 citations. Twenty-one studies, containing 4251 subjects,
reported the prevalence of postoperative complications according to preoperative anti-TNF
treatment. Pooled prevalence of any postoperative complication was 21%, 35%, and 26% in
Crohn's disease (CD), ulcerative colitis (UC) or inflammatory bowel disease unspecified (IBD-U)
and IBD, respectively. The prevalence of any postoperative complication was increased in IBD
patients who underwent preoperative anti-TNF therapy (OR: 1.25; 95% CI: 1.02–1.53). Pooled
prevalence of infectious postoperative complications was 16%, 17%, and 15% in CD, UC/IBD-U
and IBD, respectively. The prevalence of infectious postoperative complications was increasednt of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Université Henri Poincaré 1, Allée
cy, France. Tel.: +33 3 83 15 36 31; fax: +33 3 83 15 36 33.
ail.com (L. Peyrin-Biroulet).
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854 V. Billioud et al.in CD patients who underwent preoperative anti-TNF therapy (OR: 1.45; 95% CI: 1.03–2.05).
The confounding effect of concomitant therapies could not be studied.
Conclusions: Preoperative anti-TNF use slightly increases the occurrence of overall postoper-
ative complications in IBD patients, and particularly infectious complications in CD patients.
Postoperative complications are not increased in UC.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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Nearly one-third of Crohn's disease (CD) patients still require a
major abdominal resection in the 5 years following disease
diagnosis in the era of biologic therapy.1,2 About one-tenth
of patients still require colectomy for UC at 5 years in the
era of biologics.3,4 Anti-tumor necrosis factor (TNF) agents
are increasingly used in inflammatory bowel disease (IBD)
patients. Up to 60% of CD patients received an anti-TNF before
first abdominal surgery.2 Almost one-third of CD patients
receive an anti-TNF treatment in the 6 months preceding a
small bowel resection.5 A recent study showed that between
ulcerative colitis (UC) diagnosis and colectomy, 30% of
patients received at least one anti-TNF agent.4 The influence
of biologic agents on postoperative outcomes is therefore of
particular interest in clinical practice.
Most studies focusing on CD patients have failed to dem-
onstrate that preoperative anti-TNF therapy could alter
postoperative outcomes.6–14 However, the largest study has
shown that infliximab use within the 3 months before sur-
gery is associated with increased postoperative sepsis and
abscess in CD patients.15 In UC, a meta-analysis found
that infliximab is associated with an increased risk of over-
all short-term post-operative complications.16 Subsequentstudies failed to show a negative impact of anti-TNF therapy
on postoperative outcomes.17–22 As a result, there remains
controversy as to whether exposure to anti-TNF therapy
prior to surgery is associated with higher rates of postoper-
ative complications.
We have therefore performed a systematic review and a
meta-analysis of the existing studies exploring the associa-
tion between pre-operative anti-TNF treatment and early
postoperative complications in patients with IBD. The aims
of our study were to determine if preoperative anti-TNF use
affects overall postoperative complications, infectious com-
plications, or non-infectious complications in IBD patients,
and for CD or UC patients separately.2. Methods
2.1. Search strategy and study selection
A search of the medical literature was conducted in MEDLINE
indexed literature using the PubMed search engine from
the National Center for Biotechnology Information (http://
www.pubmed.gov) (January 1966 to January 2012). Obser-
vational studies evaluating the effect of preoperative anti-
Table 1 Eligibility criteria.
Observational studies
Adults (N50% of patients aged N16 years)
Inflammatory bowel disease patients: Crohn's disease, ulcerative colitis, and/or inflammatory bowel disease unspecified
Patients undergoing abdominal surgery
Compared patients preoperatively treated or not treated with anti-TNF a
Assessment of early overall, infectious, or non-infectious postoperative complications b
a Infliximab, adalimumab or certolizumab.
b Within 30 days postoperatively.
855Anti-TNF and postoperative complicationsTNF therapy on postoperative complications in patients with
CD and/or UC and/or inflammatory bowel disease unspeci-
fied (IBD-U) requiring abdominal surgery were eligible for
inclusion. Only studies assessing short-term postoperative
complications were included (within 30 days after surgery).
Studies could report the total number of complications, or
infectious, or non-infectious complications. Studies evalu-
ating any type of anti-TNF therapy (infliximab, adalimumab,
or certolizumab) were considered eligible. Studies evaluat-
ing only pediatric patients were excluded (Table 1).
Studies were identified using the following search terms:
“postoperative complications” as medical subject headings
(MeSH) as well as postoperative and perioperative as free text
terms. These were combined using the set operator AND with
studies identified with the search term “tumor necrosis
factor-alpha/antagonist and inhibitors” as MeSH, as well as
anti TNF, infliximab, adalimumab, or certolizumab as free
text terms. Finally, thesewere combined using the set operator
AND with studies identified with the search terms “inflamma-
tory bowel disease”, “colitis, ulcerative” and “Crohn disease”
as MeSH, as well as inflammatory bowel disease, ulcerative
colitis and Crohn's disease as free text terms. The literature
search was restricted to English language articles. Manual
searches of reference lists from potentially relevant papers
were used to identify any additional studies that may haveFigure 1 Flow diagram of assessment of stubeen missed using the electronic search. We also conducted
a manual search of abstracts from the European Crohn's
and Colitis Organisation, the American Gastroenterological
Association Digestive Diseases Week, and the United European
Gastroenterology Week (all from 2008 to 2011 inclusive)
congresses.
Studies were assessed independently by two investiga-
tors (VB, XR), according to the pre-defined eligibility criteria.
Any disagreements in eligibility assessment were resolved
by consensus. This manuscript follows the criteria of the
‘Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) Group’.23
2.2. Data extraction
Data were extracted independently by two investigators
onto a Microsoft Excel spreadsheet (XP professional edition;
Microsoft, Redmond, WA), with discrepancies resolved by
consensus. The following data were collected for each study:
total number of CD and UC patients treated with anti-TNF
prior to surgery, total number of patients not treated with
anti-TNF prior to surgery, and the number of CD and/or UC
patientswho experienced at least one overall and/or infectious
and/or non-infectious postoperative complications in both the
anti-TNF and the non anti-TNF group. In addition, the followingdies identified in the systematic review.
Table 2 Characteristics of studies included in the meta-analysis.
Study (author, year) Type of study Type of disease Inclusion period Study
population
(N)
Patient treated
with anti-TNF(n)
Tay et al., 200314 Retrospective CD 1998–2002 100 22 (IFX: 22)
Marchal et al., 200411 Case–control CD 1998–2002 79 40 (IFX: 40)
Colombel et al., 20047 Retrospective CD 1998–2001 270 52 (IFX:52)
Appau et al., 200815 Retrospective CD 1998–2007 389 60 (IFX: 60)
Indaar et al., 20098 Retrospective CD 1999–2007 112 17
Nasir et al., 201012 Retrospective CD 2005–2009 370 119 (IFX: 69,
ADA: 47, CTZ: 3)
Canedo et al., 20116 Retrospective CD 2000–2008 225 65 (IFX: 65)
Kasparek et al., 20119 Case–control CD 2001–2008 96 48 (IFX: 48)
Syed et al., 201131 Retrospective CD 2004–2010 266 126 (IFX: 126)
Schluender et al., 200729 Retrospective UC 2000–2005 151 17 (IFX: 17)
Selvasekar et al., 200730 Retrospective UC 2002–2005 301 47 (IFX: 47)
Mor et al., 200833 Case–control UC (44) IBD-U (2) 2000–2006 92 46 (IFX: 46)
Coquet-Reinier et al., 200919 Case–control UC 1999–2008 26 13 (IFX: 13)
Ferrante et al., 200927 Retrospective UC (134) IBD-U (7) 1998–2008 141 22 (IFX: 22)
Gainsbury et al., 201120 Retrospective UC 2005–2009 81 29 (IFX: 29)
Bregnbak et al., 201118 Retrospective UC 2005–2010 71 20 (IFX: 20)
De Silva et al., 201122 Retrospective UC 1996–2009 666 34 (IFX: 34)
Eshuis et al., 201032 Retrospective UC 2006–2009 39 17 (IFX: 17)
Kunikate et al., 200810 Retrospective CD (188) UC (156) IBD-U (69) 1993–2007 413 101 (IFX: 101)
Regadas et al., 201128 Retrospective UC (224) CD (21) IBD-U (4) 2001–2008 249 28 (IFX: 28)
Rizzo et al., 201113 Retrospective CD (76) UC (38) 2004–2010 114 d 54 (IFX:41,
ADA:12, CTZ:1)
Note: CD: Crohn's disease; UC: ulcerative colitis; IBD-U: inflammatory bowel disease unspecified; IFX: infliximab, ADA: adalimumab, CTZ:
certolizumab; IS: immunosuppressor, Cyclo: cyclosporin; S: steroids; IPAA: ileal pouch anal anastomosis; na: non avalaible.
a 10 day complications included in the analysis only.
b Some patients received anti-TNF up to 30 days postoperatively.
c Overall and infectious complication rate not available for one stage IPAA.
d A group of control patients (anti-TNF therapy more than 12 months preoperatively) was not included in the analysis.
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type of study, inclusion period, overall study population, type
of anti-TNF therapy, anti-TNF treatment duration, time since
last anti-TNF injection/infusion, concomitant medications,
type of surgery, and duration of follow-up after surgery.
To calculate overall postoperative complication rates,
infectious and non-infectious complications were not pooled,as one patient could suffer from more than one complication.
Similarly, infectious complications were not subtracted from
the total number of complications in order to determine the
non-infectious complication rate. In studies providing major
and minor complication rates separately, the two data were
not pooled and only major complications were included in the
analysis.
Anti-TNF treatment
duration (median/mean
number of infusions
(IQR/SD))
Time since
last anti-TNF
treatment
(weeks)
Concomitant
medication in the
anti-TNF group
(n(%))
Concomitant
medication in
the non-anti-TNF
group (n(%))
Type of surgery Postoperative
follow-up
duration
(days)
na na IS:20 (91) IS: 50 (64) First resection with
anastomosis or
strictureplasty
28
4 (1–10) 12 (78%) IS: 24 (60) S: 12 (30) IS: 11 (29) S: 12 (30) Small bowel resection,
ileo-colonic resection,
eft colectomy or
abdomino-perineal
rectal excision
90 a
1 (1–2) 8 b na na Surgical resection,
stricturoplasty,
intestinal bypass
30
na 12 IS: 37 (62) S: 39 (65) IS: 55 (17) S: 253 (77) Ileocolonic resection 30
na 8 IS: 8 (47) S: 10 (59) IS: 31 (32.6) S: 37 (39) Instetinal resection 30
na 8 b IS: 32 (27) S: 37 (31) IS: 83 (33) S: 114 (45) Operations resulting in
some form of suture or
staple line at risk
30
na 12 na na Intestinal or colorectal
resection
na
na 12 IS: 35 (73) S: 45 (94) IS: 35 (73) S: 45 (94) Abdominal surgery 5
na 8 na na Intra-abdominal surgery na
2 (1–9) 2 (median) IS: 16 (94) Cyclo:
(29) S: 17 (100)
IS: 59 (44) Cyclo:
56 (42) S: 134(100)
Subtotal colectomy
or IPAA
30
na 24 IS: 43 (92) S: 42 (89) IS: 112 (44) S: 218 (88) IPAA 30
3 (2–4) 13.5 (median) IS: 18 (39) IS: 13 (28) Two stage IPAA 30
5 (+/−3.5) 1.5 (median) IS: 7 (54) Cyclo:
2 (15) S: 6 (46)
IS: 1 (8) Cyclo:
7 (54) S: 5 (38)
Laparoscopic RPC with IPAA 30
2.5 (2–3) 12 IS: 13 (59) S: 14 (64) IS: 65 (59) S: 82 (69) Restorative proctocolectomy 30
na 12 IS: 24 (82.8) S: 27 (93.1) IS: 28 (53.8) S: 36 (69.2) IPAA 30
1.7 (1–2) 12 IS:5 (25) S: 15 (75) IS: 16 (31.4) S: 33 (64.7) Colectomy 30
na na na na Total abdominal colectomy,
subtotal colectomy, or
proctocolectomy
na
na na na na Two stage IPAA c na
na 12 IS: 37 (37) S: 76 (75) IS: 81 (26) S: 240 (77) Abdominal surgery 30
na 8 IS: 15(53.6) S: 18(64.3) IS: 35 (16) S: 107 (49) Ileostomy reversal 30
na 12 (IFX) 4
(ADA, CTZ)
IS: 21 (39) S: 19 (35) IS: 13 (22) S: 29 (48) CD- or UC-related
abdominal surgery
30
857Anti-TNF and postoperative complications2.3. Data synthesis and statistical analysis
The proportion of individuals with overall, infectious and
non-infectious postoperative complication in each study was
combined to give a pooled prevalence of postoperative
complication for studies including CD, UC/IBD-U or IBD patients.
Heterogeneity between studies was assessed using the I2statistic with a cutoff of 50%,24 and the χ2 test with a
P valueb0.10, used to define a statistically significant degree
of heterogeneity. Data were pooled using a random effects
model,25 to give a more conservative estimate of the
prevalence of postoperative complication and the odds of a
postoperative complication in these various groups. StatsDirect
version 2.7.2 (StatsDirect, Sale, Cheshire, UK) was used to
Table 3 Postoperative complications in anti-TNF treated patients.
Study
(author,
year)
Overall complications Infectious complications Non-infectious complications
Study
population
n(%)
Definition Non-anti-
TNF group
n (%)
Anti-TNF
group
n (%)
Study
population
n (%)
Definition Non-anti-
TNF group
n (%)
Anti-TFN
group
n (%)
Anti-TFN
group,
details (n)
Study
population
n (%)
Definition Non-anti-
TNF group
n (%)
Anti-TFN
group
n (%)
Anti-TFN group,
details (n)
Tay et al.,
200314
na na na na 11 (11) Intra-abdominal
septic
complications:
abscess, fistula,
and anastomotic
leak which
required
intravenous
antibiotics, a
drainage
procedure, or
reexploration
8 (10) 3 (14) Abscess (2)
Leak (1)
na na na na na
Marchal
et al.,
200411
8 (10) Early major
complications b
(sepsis,
anastomotic leak,
peritonitis, local
fistula or abscess,
wound infection,
wound failure,
severe anemia,
bulbar ulcer
bleeding)
3 (8) 5 (13) 7 (9) Catheter
infection
Wound infection
Upper airway
infection
Infectious
diarrhea
Yeast infection
(both major and
minor
complications)
1 (3) 6 (15) Catheter
sepsis (2)
Wound
infection (1)
Upper airway
infection (1),
Infectious
diarrhea (2)
Oral–
pharyngeal
candidiasis (2)
na na na na na
Colombel
et al.,
20047
63 (23.3) na 51 (23) 12 (23) 52 (19) Wound sepsis
Intra-abdominal
infection
Extra-abdominal
infection
43 (20) 9 (17) na 18 (7) CD recurrence
Small bowel
obstruction
Gastrointestinal
bleeding
Thromboembolism
na na na
Appau
et al.,
200815
46 (12) na 33 (10) 13 (22) 45 (12) Wound
dehiscence
Sepsis
33 (10) 12 (20) Intra-abdominal
abscess (6)
Anastomotic
leak (6)
1 (1) Urinary
complication
0 (0) 1 (1) Urinary
complication
(1)
Indaar
et al.,
20098
33 (29.5) Anastomotic leak
Enterocutaneous
fistula
Gracilis flap
necrosis
Intra-abdominal
abscess
Intraoperative
bleeding
Myocardial
infarction
Pneumonia rectal
stump leak
Wound dehiscence
Postoperative
27 (28) 6 (35) na na na na na na na na na na
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bleeding Wound
infection
Non-oliguric renal
failure
Thrombosis upper
limb
Prolonged ileus
Urinary tract
infection
Nasir et al.,
201012
106 (28.6) na 70 (28) 36 (30) 9 (3) Intra-abdominal
abscess
Anastomotic
leaks
5 (3) 4 (2) na na na na na na
Canedo
et al.,
20116
na na na na 57 (25) Wound infection
Pulmonary
infection
Abscess
Anastomotic
leakage a
41 (26) 16 (25) Wound
infection (9)
Pulmonary
infection (1)
Abscess (2)
Anastomotic
leakage (2)
na na na na na
Kasparek
et al.,
20119
25 (26) Major
complication b
(anastomotic leak,
intraabdominal
abscess, small
bowel leakage,
stoma
complication,
postoperative
hemorrhage,
enterocutaneous
fistula)
12 (25) 13 (27) na na na na na na na na na na
Syed et al.,
201131
na na na na 87 (33) na 38 (27) 49 (39) na na na na na na
Schluender
et al.,
200729
43 (28) Pneumonia
Deep vein
thrombosis
Pancreatitis
Acute renal failure
Cerebrovascular
accident
Dehydration
Superficial
thrombophlebitis
Pyoderma
gangrenosum
Urinary retention
Readmission for
small-bowel
obstruction
Large peristomal
abscess
Rectal stump leak
37 (28) 6 (35) 14 (9) na 11 (8) 3 (18) na na na na na na
(continued on next page)
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Table 3 (continued)
Study
(author,
year)
Overall complications Infectious complications Non-infectious complications
Study
population
n(%)
Definition Non-anti-
TNF group
n (%)
Anti-TNF
group
n (%)
Study
population
n (%)
Definition Non-anti-
TNF group
n (%)
Anti-TFN
group
n (%)
Anti-TFN
group,
details (n)
Study
population
n (%)
Definition Non-anti-
TNF group
n (%)
Anti-TFN
group
n (%)
Anti-TFN group,
details (n)
Superficial wound
infection
Ileus
Bleeding requiring
transfusion or
reoperation
Selvasekar
et al.,
200730
153 (50.8) na 124 (49) 29 (62) 38 (13) Anastomotic leak
Pelvic abscess
Wound infections
25 (10) 13 (28) na na na na na na
Mor et al.,
200833
23 (50) na 7 (15) 16 (35) 11 (24) Pelvic sepsis 1 (2) 10 (28) na na na na na na
Coquet-
Reinier
et al.,
200919
8 (31) Small bowel
obstruction
Pelvic abscess
Pneumoperitoneum
Anastomotic leak
Pleural effusion
Anastomotic
Hemorrhage
Small bowel
perforation
5 (39) 3 (23) 2 (8) Pelvic abscess
Anastomotic
leak a
1 (8) 1 (8) Pelvic abscess
(1)
6 (23) Small bowel
obstruction
Pneumoperitoneum
Pleural effusion
Anastomotic
Hemorrhage
Small bowel
perforation a
4 (31) 2 (15) Small bowel
obstruction (1)
Pneumoperitoneum
(1)
Ferrante
et al.
200927
na na na na 31 (22) Anastomotic leak
Pelvic abscess
Wound infection
Nonsurgical site
infectious
29 (24) 2 (9) Wound
infection (1)
Nonsurgical site
infection (1)
na na na na na
Gainsbury
et al
201120
36 (44) Pouch/anastomotic
leak
Pelvic/
intraabdominal
abscess
Pouch-related
complications
Wound infection
Others
(thrombosis, small
bowel obstruction,
ileus, and one
episode of wound
dehiscence)
23 (44) 13 (45) 19 (24) Pelvic/
intraabdominal
abscess wound
infection
14 (27) 5 (17) Pelvic/
intraabdominal
abscess (4)
wound
infection (1)
28 (35) Pouch/anastomotic
leak,
pouch-related,
other
16 (31) 12 (41) Other (12)
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Bregnbak
et al.,
201118
35 (49) na 25 (49) 10 (50) 25 (35) na 21 (41) 4 (20) Wound
infection (1)
Abscess (1)
Pneumonia (1)
Epididymitis (1)
16 (23) na 10 (18) 6 (30) Ileus (6)
Wound rupture
(1)
De Silva
et al.,
201122
180 (27) Unexpected
medical events
that occurred
between the start
of the surgery and
discharge from the
hospital
172 (96) 8 (4) na na na na na na na na na na
Eshuis
et al.,
201032
16 (41) na 8 (36) 8 (47) 11 (28) na 5 (23) 6 (35) na 9 (23) na 3 (14) 6 (35) na
Kunikate
et al.,
200810
67 (16) Infectious
Hypomotility
Cardiac
Hepato-renal
Bleeding
Anastomotic leak
49 (16) 17 (17) 38 (9) Pneumonia,
sepsis
Anastomotic leak
Enterocutaneous
Fistula
Wound infection/
dehiscence
Intra-abdominal
abscess
32 (10) 6 (6) na na na na na na
Regadas
et al.,
201128
32 (13) Infectious
complications
Small bowel
obstruction
31 (14) 1 (4) 22 (9) Wound infection
Anastomotic leak
Intra-abdominal
abscess
Enterocutaneous
fistula
Clinical sepsis
22 (10) 0 (0) na 10 (4) Small bowel
obstruction
9 (4) 1 (4) Small bowel
obstruction (1)
Rizzo
et al.,
201113
24 (21) Infectious
complications
Hypomotility
complications
Thrombotic
complications
Bleeding requiring
re-surgery
Anastomotic leak
Cardiac and/or
hepatorenal failure
10 (17) 14 (26) 17 (15) Pneumonia
Sepsis
Wound infection
Intra-abdominal
abscess
8 (13) 9 (17) na na na na na na
a Defined by VB and XR.
b Minor complication not included in analysis.
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Figure 2 Pooled odds ratio for overall postoperative complications (A) and infectious complications (B) in anti-TNF and non-anti-TNF
treated CD patients.
862 V. Billioud et al.generate Forest plots of pooled prevalences and pooled
ORs with 95% CIs. We planned to assess for the evidence of
publication bias by applying Egger's test to funnel plots of Ors
when a sufficient number of studies (more than ten) existed.263. Results
3.1. Literature search results
The search strategy identified 86 citations. We identified 30
papers that appeared to be relevant to the study question.From these, thirteen studies were excluded. Finally, 17 ob-
servational studies reporting short-term postoperative com-
plications in patients treated preoperatively with anti-TNF
were included in the analysis. Manual searches of reference
list and abstracts identified 4 additional studies resulting in a
total of 21 studies including 4251 patients from whom 977
were treated with anti-TNF (Fig. 1).
Seventeen of the studies were retrospective case
series.6–8,10,12–15,18,20,22,27–32 We also identified 4 case–
control studies.9,11,19,33 The study populations included CD
patients, UC/IBD-U patients and both UC/IBD-U and CD
patients in 9,6–9,11,12,14,15,31 918–20,22,27,29,30,32,33 and 310,13,28
863Anti-TNF and postoperative complicationsstudies respectively. The individual study characteristics are
provided in Table 2. Individual postoperative complication
rate and definitions are provided in Table 3.
3.2. Short-term postoperative complications in CD
patients treated with anti-TNF
3.2.1. Overall complications
Six studies assessed overall postoperative complications in
CD patients treated or not treated with anti-TNF pre-
operatively, and included a total of 1316 patients.7–9,11,12,15 A
total of 281 (21%) CD patients experienced any postoperativeFigure 3 Pooled odds ratio for overall postoperative complications
treated UC/IBD-U patients.complication, 85 (25%) among 336 patients receiving anti-TNF
compared with 196 (20%) of 980 patients not treated with
anti-TNF. There was no statistically significant difference
detected between anti-TNF and non-anti-TNF treated CD
patients for any postoperative complication (OR: 1.31; 95% CI:
0.96–1.77) (Fig. 2A), with no statistically significant hetero-
geneity detected between studies (I2=0%, P=0.50).
3.2.2. Infectious complications
Seven studies assessed infectious postoperative com-
plications in CD patients treated or not treated with
anti-TNF preoperatively, and included a total of 1699(A) and infectious complications (B) in anti-TNF and non-anti-TNF
864 V. Billioud et al.patients.6,7,11,12,14,15,31 A total of 268 (16%) CD patients
experienced an infectious postoperative complication, 99
(21%) of 484 patients receiving anti-TNF compared with 169
(14%) of 1215 patients not treated with anti-TNF. There
was a significantly higher rate of infectious postoperative
complications in anti-TNF treated CD patients (OR: 1.45; 95%
CI: 1.03–2.05) (Fig. 2B), with no statistically significant het-
erogeneity detected between studies (I2=14.8%, P=0.31).
3.3. Short-term postoperative complications in UC
or IBD-U patients treated with anti-TNF
3.3.1. Overall complications
Eight studies assessed overall postoperative complica-
tions in UC/IBD-U patients treated or not treated with
anti-TNF preoperatively, and included a total of 1427
patients.18–20,22,29,30,32,33 A total of 494 (35%) UC/IBD-U
patients experienced any postoperative complication, 93 (41%)
of 223 patients receiving anti-TNF compared with 401 (33%)
of 1204 patients not treated with anti-TNF. There was no
statistically significant difference detected between anti-TNF
and non-anti-TNF treated UC/IBD-U patients for any postoper-
ative complication (OR: 1.32; 95% CI: 0.94–1.84) (Fig. 3A), with
no statistically significant heterogeneity detected between
studies (I2=0%, P=0.51).
3.3.2. Infectious complications
Eight studies assessed infectious postoperative compli-
cations in UC/IBD-U patients treated or not treated with
anti-TNF preoperatively, including a total of 902 patients. A
total of 151 (17%) UC/IBD-U patients experienced an infec-
tious postoperative complication, 44 (21%) of 211 patients who
received anti-TNF compared with 107 (16%) of 691 patients
not treated with anti-TNF. There was no statistically signifi-
cant difference detected between anti-TNF and non-anti-TNF
treated UC/IBD-U patients for infectious postoperative com-
plications (OR: 1.31; 95% CI: 0.55–3.07) (Fig. 3B), but with
statistically significant heterogeneity detected between stud-
ies (I2=67.6%, P=0.003).
3.3.3. Non-infectious complications
Four studies assessed non-infectious postoperative com-
plications in UC/IBD-U patients treated or not treated
with anti-TNF preoperatively, and included a total of 217
patients.18–20,32 A total of 59 (27%) UC/IBD-U patients
experienced a non-infectious postoperative complication,
26 (33%) of 79 patients who received anti-TNF compared
with 33 (24%) of 138 patients not treated with anti-TNF.
There was no statistically significant difference detected
between anti-TNF and non-anti-TNF treated UC/IBD-U patients
for non-infectious postoperative complications (OR: 1.60; 95%
CI: 0.85–3.00) (Supplementary Fig. 1), with no statistically
significant heterogeneity detected between studies (I2=0%,
P=0.41).
3.4. Short-term postoperative complications in IBD
patients treated with anti-TNF
3.4.1. Overall complications
Seventeen studies assessed overall postoperative com-
plications in IBD patients treated or not treated withanti-TNF preoperatively, and included a total of 3519
patients.7–13,15,18–20,22,28–30,32,33 A total of 897 (26%) IBD
patients experienced any postoperative complication, 210
(28%) of 742 patients who received anti-TNF compared with
687 (25%) of 2777 patients not treated with anti-TNF. There
was a significantly higher rate of any postoperative compli-
cation in anti-TNF treated IBD patients (OR: 1.28; 95% CI:
1.04–1.57) (Fig. 4A), with no statistically significant hetero-
geneity detected between studies (I2=0%, P=0.58), and no
evidence of funnel plot asymmetry (Egger test, P=0.54).
3.4.2. Infectious complications
Eighteen studies assessed infectious postoperative com-
plications in IBD patients treated or not treated with
anti-TNF preoperatively, and included a total of 3377
patients.6,7,10–15,18–20,27–33 A total of 496 (15%) IBD patients
experienced an infectious postoperative complication, 158
(18%) of 878 patients who received anti-TNF compared with
338 (14%) of 2499 patients not treated with anti-TNF agents.
There was no statistically significant difference detected
between anti-TNF and non-anti-TNF treated IBD patients
for infectious postoperative complications (OR: 1.27; 95% CI:
0.87–1.85) (Fig. 4B), but with statistically significant hetero-
geneity between studies (I2=51.5%, P=0.006). There was no
evidence of funnel plot asymmetry (Egger test, P=0.67).
3.4.3. Non-infectious complications
Six studies assessed non-infectious postoperative com-
plications in IBD patients treated or not treated with
anti-TNF preoperatively, and included a total of 855
patients.15,18–20,28,32 A total of 70 (8%) IBD patients ex-
perienced a non-infectious postoperative complication, 28
(17%) of 167 patients who received anti-TNF compared with
42 (6%) of 688 patients not treated with anti-TNF agents.
There was no statistically significant difference detected
between anti-TNF and non-anti-TNF treated IBD patients
for non-infectious postoperative complications (OR: 1.65;
95% CI: 0.89–3.06) (Supplementary Fig. 2), with no statisti-
cally significant heterogeneity detected between studies
(I2 =4.7%, P=0.39).
4. Discussion
The present meta-analysis shows that pre-operative treat-
ment with anti-TNF was associated with a small, but
statistically significant, increase in overall post-operative
complication rates in IBD in the short-term. We also found
a significant association between pre-operative anti-TNF
use and short-term infectious complications in CD patients.
To our knowledge, to date, no meta-analysis has assessed
the impact of anti-TNF therapy in the perioperative setting
in CD patients.
Among the 9 studies including a total of 1907 CD patients,
only two studies found that preoperative anti-TNF could lead
to more postoperative complications.15,31 By pooling 484 CD
patients who received preoperative anti-TNF therapy, we
were able to demonstrate that the prevalence of infectious
postoperative complications in CD patients is increased,
with an OR of 1.45. This is comparable to the risk related to
the use of systemic glucocorticosteroids, which has been
estimated in a previous meta-analysis as 68%.34 Interestingly,
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866 V. Billioud et al.this is in line with the largest study included, which showed
that infliximab use is associated with 30-day postoperative
readmission, sepsis, and intra-abdominal abscess.18 This study
accounted for only 23% of all CD patients included in the
calculation of the postoperative infectious complication risk in
our meta-analysis.18
Interestingly, the present meta-analysis failed to identify
an increased risk of overall, infectious or non-infectious
complications in UC patients receiving anti-TNF preopera-
tively. In a previous meta-analysis including 706 patients,
Yang et al. found that pre-operative treatment with
infliximab increased by 80% short-term total post-operative
complications in UC.16 However, as clearly stated by the
authors, their analysis was underpowered due to the small
number of studies and high degree of heterogeneity among
studies.16 Five studies have been published since which
were all negative.18–20,22,32 By pooling 1427 UC patients,
we were able to show that preoperative anti-TNF therapy
is not associated with an increased rate of overall post-
operative complications in the short-term. Considering a
three-stage IPAA, rather than a two-stage procedure, has
been proposed in UC patients receiving anti-TNF close to
the time of surgery.35,36 Our results do not support such a
strategy.
The present meta-analysis has several limitations. Most
of the studies were retrospective ones. The possible mis-
takes of the retrospective analysis may add during the
meta-analysis and not all the confounding factors can
be controlled in these observational studies. For instance,
nutritional status and training of the surgeonwere not analyzed
while they are known to affect postoperative outcomes.21,37
Concomitant immunomodulator and glucocorticosteroids were
used in nearly all groups of anti-TNF patients, but the rates
of their use were not similar in anti-TNF treated and control
groups in most studies.10–13,15,20,29,30 The use of such concom-
itant treatment is missing in five studies.6,7,22,31,32 Steroid
doses are not detailed in most of the studies. Immunosuppres-
sive therapy, such as azathioprine, does not seem to affect
postoperative outcomes, whereas glucocorticosteroids in-
creased postoperative complications, particularly infectious
ones, in a dose dependant manner.7,34,38 There was also a lack
of adjustment for disease severity. Furthermore, duration of
follow-up is unknown in four studies.6,22,31,32 The duration of
follow-up was only 5 days in one study which could be not
enough to evaluate postoperative complications.9 Sensitivity
analysis excluding this study was performed (Supplementary
Fig. 3). Another limitation of several of these studies is the
relatively long pre-operative IFX window, often 12 weeks or
more. This should be balanced with pharmacokinetics data,
which suggest that the half-life of infliximab is between 7
and 18.5 days.39 In addition, preoperative anti-TNF dura-
tion is not provided in 14 studies and is less than 3 injections
in 4 others.6–10,12–15,18,20,22,27–32 Finally, if patients re-
ceived induction therapy could not be assessed. This could
have underestimated the influence of anti-TNF on postop-
erative outcomes. The strengths of our meta-analysis are
the large number of studies, and hence patients, included in
the analysis, the well-described and rigorous methodology,
and the analysis of overall, infectious and non-infectious
complications.
In conclusion, the present study suggests that preopera-
tive anti-TNF therapy could be associated with a higher rateof overall postoperative complications in IBD patients, with
an increased risk of postoperative infections in CD. UC
patients receiving preoperative anti-TNF treatment do not
seem to be at an increased risk of experiencing postoper-
ative complications. In the present study, the confounding
effect of concomitant therapies could not be studied.
Further prospective studies about the relationship be-
tween anti-TNF and post-operative complications, able to
control potential confounding factor and using homoge-
neous classification of postoperative complications, are
keenly awaited before definitive recommendations can be
made.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.crohns.2013.01.014.
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